BMAT Regulatory Frameworks & Compliance 2 — Questions and Answers
Question 1: Under the FDA's 21 CFR Part 11, which of the following is a requirement for electronic records used in clinical trials?
- Paper backup must always accompany electronic records
- Electronic signatures must be linked to their respective electronic records (Correct answer)
- Electronic records are only valid if notarized by a third party
- Electronic systems must be operated solely on government-approved hardware
Correct answer: Electronic signatures must be linked to their respective electronic records
21 CFR Part 11 requires that electronic signatures be linked to their respective electronic records to ensure integrity and non-repudiation.
Question 2: The Belmont Report established three core principles for ethical research. Which of the following correctly identifies all three?
- Autonomy, Beneficence, Non-maleficence
- Respect for Persons, Beneficence, Justice (Correct answer)
- Informed Consent, Risk Minimization, Fair Selection
- Privacy, Confidentiality, Voluntary Participation
Correct answer: Respect for Persons, Beneficence, Justice
The Belmont Report (1979) established Respect for Persons, Beneficence, and Justice as the three foundational principles for ethical research involving human subjects.
Question 3: A pharmaceutical company wants to market a new drug in the EU. Under the EMA centralized procedure, which body issues the final marketing authorization?
- The European Medicines Agency (EMA) directly
- The European Commission (Correct answer)
- The Committee for Medicinal Products for Human Use (CHMP) alone
- Individual EU member state health ministries
Correct answer: The European Commission
While the CHMP issues a scientific opinion, the European Commission grants the final marketing authorization valid across all EU member states.
Question 4: Which phase of a clinical trial first tests a new drug in humans, typically focusing on safety and dosing?
- Phase II
- Phase III
- Phase I (Correct answer)
- Phase IV
Correct answer: Phase I
Phase I trials are the first studies in humans, enrolling a small number of participants (often healthy volunteers) to assess safety, tolerability, and pharmacokinetics.
Question 5: Under HIPAA's Privacy Rule, a 'covered entity' that discloses protected health information (PHI) without authorization could face which type of penalty?
- Only criminal penalties apply to HIPAA violations
- Only civil monetary penalties apply to HIPAA violations
- Both civil monetary penalties and criminal penalties can apply (Correct answer)
- Penalties are solely determined by state law
Correct answer: Both civil monetary penalties and criminal penalties can apply
HIPAA enforcement includes both civil monetary penalties (tiered by culpability) and criminal penalties for willful violations, applied by OCR and the DOJ respectively.
Question 6: The ICH E6(R2) Good Clinical Practice (GCP) guideline was updated primarily to address which emerging challenge in clinical research?
- The use of social media in patient recruitment
- Risk-based monitoring approaches and electronic data capture (Correct answer)
- Mandatory use of placebo controls in all trials
- Standardizing patient-reported outcome measures globally
Correct answer: Risk-based monitoring approaches and electronic data capture
ICH E6(R2) updated the original GCP guideline to incorporate risk-based quality management approaches and reflect the increasing use of electronic systems in clinical trials.
Question 7: A researcher collects biological samples from patients and plans to use them in future, unspecified studies. Under the Common Rule (45 CFR 46), what is typically required?
- A one-time blanket waiver from the IRB is sufficient for all future uses
- Broad consent covering future research use, with IRB approval (Correct answer)
- No consent is needed if samples are de-identified before storage
- Samples can only be used for the original study purpose with no exceptions
Correct answer: Broad consent covering future research use, with IRB approval
The revised Common Rule introduced a 'broad consent' mechanism allowing institutions to obtain consent for future, unspecified secondary research on stored biospecimens.
BMAT Regulatory Frameworks & Compliance 2
Under the FDA's 21 CFR Part 11, which of the following is a requirement for electronic records used in clinical trials?